Paper39710092
Fusion circRNA F-circEA1 facilitates EML4-ALK1 positive lung adenocarcinoma progression through the miR-4673/SMAD4/ADAR1 axis.
Huo Y and 3 others. Cell Signal, 2025. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Fusion circRNA F-circEA1 facilitates EML4-ALK1 positive lung adenocarcinoma progression through the miR-4673/SMAD4/ADAR1 axis. Papers, record 39710092. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39710092
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fusion circRNA F-circEA1 facilitates EML4-ALK1 positive lung adenocarcinoma progression through the miR-4673/SMAD4/ADAR1 axis.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| MicroRNAs | Major topic |
| Adenocarcinoma of Lung | Major topic |
| RNA, Circular | Major topic |
| Lung Neoplasms | Major topic |
| Smad4 Protein | Major topic |
| Oncogene Proteins, Fusion | Major topic |
| RNA-Binding Proteins | Major topic |
| Adenosine Deaminase | Major topic |
| Humans | |
| Disease Progression | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Gene Expression Regulation, Neoplastic | |
| Cell Movement | |
| Signal Transduction |
Source PubMed
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42794955 | Circular RNAs in NSCLC: Their Role in Tumorigenesis, Tumor Microenvironment Reshaping, and Response to Therapies. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42794955 | PubMed |
| 41828906 | Regulatory Effect of circRNA3890 on the Establishment of Receptive Endometrium in Dairy Goats. | Animals (Basel) | 2026 | https://conductscience.org/library/papers/41828906 | PubMed |
| 40861257 | Mirtrons in Human Cancers. | Onco (Basel) | 2025 | https://conductscience.org/library/papers/40861257 | PubMed |
| 40782195 | ADAR1-mediated RNA editing in breast cancer: molecular mechanisms and therapeutic implications. | Med Oncol | 2025 | https://conductscience.org/library/papers/40782195 | PubMed |
| 40495384 | Targeting RNA adenosine editing and modification enzymes for RNA therapeutics. | Mol Ther | 2025 | https://conductscience.org/library/papers/40495384 | PubMed |
Genes5
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ADAR | 103 | PubTator's text mining | https://conductscience.org/library/genes/103 | NCBI Gene |
| EML4 | 27436 | PubTator's text mining | https://conductscience.org/library/genes/27436 | NCBI Gene |
| MIR4673 | 100616242 | PubTator's text mining | https://conductscience.org/library/genes/100616242 | NCBI Gene |
| SLPI | 6590 | PubTator's text mining | https://conductscience.org/library/genes/6590 | NCBI Gene |
| SMAD4 | 4089 | PubTator's text mining | https://conductscience.org/library/genes/4089 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39710092
GET https://conductscience.org/api/papers/v1/39710092/authors